Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.20.

STOK has been the topic of several recent research reports. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright dropped their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th.

Stoke Therapeutics Trading Down 0.6%

Shares of STOK stock traded down $0.07 during trading hours on Monday, hitting $11.49. 185,804 shares of the company were exchanged, compared to its average volume of 671,101. The stock has a market capitalization of $627.08 million, a price-to-earnings ratio of 14.54 and a beta of 1.14. The firm has a fifty day simple moving average of $10.36 and a 200 day simple moving average of $9.58. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $16.15.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the sale, the insider directly owned 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Siren L.L.C. increased its stake in Stoke Therapeutics by 12.4% in the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock valued at $14,945,000 after acquiring an additional 247,347 shares during the last quarter. Jane Street Group LLC increased its position in shares of Stoke Therapeutics by 125.2% during the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock valued at $179,000 after purchasing an additional 15,001 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock valued at $11,053,000 after buying an additional 293,072 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after buying an additional 1,149 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Stoke Therapeutics in the 1st quarter worth approximately $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.